Once our proprietary device is inserted into the target tumor, the first step is to lyse a small portion of the tumor. 

Lysis causes tumor cells in the lytic zone to rupture, releasing tumor neoantigens and damage-associated molecular patterns (DAMPs) into the tumor microenvironment. The innate immune system is activated, creating an in situ vaccine.

The second step is to infuse our proprietary, multi-target drug into the lytic zone. The multi-target drug is designed to reverse immunosuppression and be highly immunostimulatory. Portions of the mixture of drug and neoantigens flow out of the tumor via the lymphatic vessels into locoregional lymph nodes. 

Flow into the lymphatics synchronizes the location of the 3 components necessary for T Cell education, namely the patient-specific neoantigens, the multi-target drug, and the immune system components in the tumor microenvironment and tumor draining lymph nodes.

The goal is to activate the immune system and combat immune suppression, resulting in effective, patient-specific T cell education.

The third step is the expansion of anti-cancer specific T cells that can recognize and destroy the cancer throughout the body and defend with immune memory.